You are viewing: US Cell Therapy Technologies Market analysis

The US Cell Therapy Technologies Market was valued at $79.5 Million in 2025 and projected to reach to $134.2 Million by 2030, representing a compound annual growth rate of 11.0%. The US cell therapy technologies market is positioned for sustained growth through 2030, driven by advancing manufacturing capabilities, declining production costs, and expanding clinical evidence supporting efficacy.

US Cell Therapy Technologies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Cell Therapy Technologies Market Trends and Insights

  • This 11.0% compound annual growth rate reflects the US healthcare sector's increasing investment in advanced cellular therapeutics and regenerative medicine solutions.
  • The US market benefits from strong regulatory frameworks, substantial R&D funding, and a mature biotechnology ecosystem that accelerates innovation and commercialization of cell-based treatments. Driving this expansion, the US market is supported by rising prevalence of chronic diseases, growing patient demand for personalized medicine, and significant pharmaceutical and biotech company commitments to cell therapy development.
  • The US regulatory environment, led by the FDA, continues to establish clear pathways for cell therapy approval, encouraging both established players and emerging startups to invest heavily in this space.
  • Between 2025 and 2030, the US is expected to maintain its position as a global leader in cell therapy innovation and adoption..

Key Market Statistics

  • CAGR (2025-2030) 11.0% CAGR
  • Market Size, 2025 ~USD 79.5 Million
  • Forecast, 2030 ~USD 134.2 Million
  • Country US

US Cell Therapy Technologies Market Overview

Market Valuation Growth :

The US cell therapy technologies market is valued at $79.5 million in 2025, with projections reaching $134.2 million by 2030, representing an 11% CAGR driven by increased adoption of cellular therapeutics.

Regulatory Advantage :

The US benefits from FDA's established regulatory pathways for cell therapies, including accelerated approval programs that facilitate faster market entry and commercialization of innovative cellular treatments.

R&D Investment Leadership :

US pharmaceutical and biotech companies lead global investment in cell therapy research, with substantial funding from NIH, private venture capital, and corporate R&D budgets supporting breakthrough innovations.

Regenerative Medicine Expansion :

Growing clinical applications in oncology, immunotherapy, and regenerative medicine are expanding the US market, with increasing hospital adoption and patient demand for advanced cellular therapeutic solutions.

US Cell Therapy Technologies Market Dynamics

  • Major pharmaceutical companies and specialized biotech firms are increasing investments in autologous and allogeneic cell therapies, particularly in CAR-T and stem cell applications.
  • Regulatory streamlining and reimbursement improvements are expected to accelerate market penetration across healthcare systems.
  • The competitive landscape will intensify as more players enter the market, while consolidation among smaller innovators continues to reshape the industry..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US cell therapy technologies market is valued at $79.5 million in 2025 and will reach $134.2 million by 2030, representing an 11.0% CAGR.
    • The US benefits from advanced regulatory frameworks and substantial R&D investments that accelerate cell therapy commercialization and adoption.
    • Rising chronic disease prevalence and demand for personalized medicine are primary growth drivers in the US market.
    • The US maintains leadership in global cell therapy innovation through its mature biotech ecosystem and FDA approval pathways.

    Cell Therapy Technologies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment MEDIA, SERA, AND REAGENTS (Product)
    Forecast Period 2025–2030
    Growth Rate CAGR of 12.4% from 2025 to 2030
    Largest Segment T-CELLS (Cell Type)
    Market Size Base Year (Billions) ~USD 4.41 (2025)
    Revenue Forecast (Billions) ~USD 7.91 (2030)
    Segments Covered Product, Type, Process, Cell Type

    US Cell Therapy Technologies Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Cell Culture Vessels
    • Cell Engineering Products
    • Cell Therapy Equipment
    • Media, Sera, And Reagents
    • Other Products
    • Systems & Software

    By Type

    • Cell Characterization
    • Cell Collection
    • Cell Expansion
    • Cell Isolation
    • Cell Processing Equipment
    • Other Cell Therapy Equipment
    • Single-Use Equipment

    By Process

    • Cell Distribution
    • Cell Handling
    • Cell Preservation
    • Cell Processing
    • Process Monitoring And Quality Control

    By Cell Type

    • Other Cells
    • Stem Cells
    • T-Cells

    US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES606.7620685.5764.7861.9982.911361335.114.3
    CELL BANKS103.8106.2113.1121.4131.6144.3160.1180.69.8
    CROS & CMOS492.5504.7550.5605.9673.8758.3864.91003.312.8
    RESEARCH INSTITUTES169.9172185.4201.5221.4246277317.111.3
    TOTAL1372.81402.91534.41693.51888.72131.424382836.113.1

    Target Audience

    • Biotech & Pharmaceutical Companies : Cell therapy developers and manufacturers need US market data to guide R&D investments, clinical trial planning, and commercialization strategies in this high-growth segment.
    • Healthcare Investors & PE Firms : Investment professionals require detailed US market analysis to evaluate funding opportunities, assess portfolio company performance, and identify acquisition targets in cell therapy.
    • Hospital & Healthcare Systems : Healthcare administrators and procurement teams use market intelligence to evaluate cell therapy adoption, budget allocation, and partnership opportunities with therapy providers.
    • Medical Device & Supply Vendors : Manufacturers of manufacturing equipment, bioreactors, and cell therapy supplies need US market insights to identify growth opportunities and develop targeted sales strategies.
    • Regulatory & Consulting Firms : Regulatory consultants and healthcare advisors require current US market data to guide clients through FDA pathways, reimbursement strategies, and market positioning.

    Key Companies in the US Cell Therapy Technologies Market

    CompanyHQOwnershipStrongest segments
    GENERAL ELECTRICUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,Additive, Components, and Other Systems,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, instruments, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor materials, specialty gases, display and OLED materials, delivery equipment),
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, filtration, fluid management, process chromatography),Lab products and services (weighing, pipettes, lab filtration, water systems, microbiological testing),Advanced analytics and PAT (BLI, cytometry screening, SPR, live-cell imaging, data analytics),
    FRESENIUS SE & CO. KGAAGermanyPublic CompanyFresenius Helios (hospitals and care centers),IV generics and IV fluids,Clinical nutrition (enteral and parenteral),
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials (mobile, semiconductor optics, aerospace, defense, sunglasses, shielding),
    TERUMO CORPORATIONJapanPublic CompanyCardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company,
    BIO-TECHNEUnited StatesPublic CompanyProtein Sciences reagents and proteomic tools,Diagnostics controls, calibrators, and assays,Spatial biology and advanced genomic assays,
    GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
    MAXCYTEUnited StatesPublic CompanyExPERT GTx and VLx (large and very large scale therapeutic applications),ExPERT STx (flow electroporation for protein production and drug development),ExPERT ATx (static electroporation for small to medium scale),

    GENERAL ELECTRIC

    General Electric is a diversified American industrial conglomerate founded in 1892 that operates across multiple sectors including power, renewable energy, aviation, and healthcare. As a public company, GE employs approximately 57,000 people globally and maintains a significant presence in industrial manufacturing and technology.

    MERCK KGAA

    Merck KGaA is a German pharmaceutical, chemical, and life sciences company founded in 1668 with approximately 59,077 employees worldwide. Operating as a public company, Merck KGaA serves customers across the healthcare, life science, and performance materials sectors.

    SARTORIUS AG

    Sartorius AG is a German life sciences and laboratory equipment company founded in 1870 with 14,242 employees. As a public company, Sartorius specializes in bioprocess solutions, laboratory instruments, and weighing technology for pharmaceutical and biotechnology industries.

    FRESENIUS SE & CO. KGAA

    Fresenius SE & Co. KGaA is a German healthcare company founded in 1912 with 177,783 employees, making it one of the largest healthcare service providers globally. Operating as a public company, Fresenius provides dialysis products and services, hospital care, and pharmaceutical products.

    CORNING INCORPORATED

    Corning Incorporated is an American materials science company founded in 1851 with 67,200 employees that specializes in glass, ceramics, and optical physics. As a public company, Corning serves industries including telecommunications, display technology, environmental solutions, and life sciences.

    TERUMO CORPORATION

    Terumo Corporation is a Japanese medical device and pharmaceutical company founded in 1921 with 30,591 employees. As a public company, Terumo develops and manufactures products for cardiovascular systems, general hospital care, transfusion and cell therapy, and vascular intervention.

    BIO-TECHNE

    Bio-Techne is an American life sciences company founded in 1976 with 3,100 employees that provides tools and reagents for research and diagnostics. Operating as a public company, Bio-Techne serves the biotechnology, pharmaceutical, and academic research sectors.

    GENSCRIPT

    GenScript is a Hong Kong-based biotechnology company founded in 2002 with 6,165 employees specializing in synthetic biology and life science research services. As a public company, GenScript provides gene synthesis, protein production, and drug discovery solutions to pharmaceutical and research organizations.

    MAXCYTE

    MaxCyte is a small American biotechnology company founded in 1998 with 91 employees focused on cell engineering and manufacturing technologies. Operating as a public company, MaxCyte develops platforms for ex vivo cell therapy production.

    Reasons to Buy this Report

    • Competitive Intelligence : Gain detailed insights into the US competitive landscape, including market leaders, emerging players, and strategic partnerships shaping the cell therapy sector through 2030.
    • Investment Decision Support : Access comprehensive market sizing and growth projections to inform investment decisions, funding allocations, and portfolio strategies in US cell therapy technologies.
    • Regulatory & Reimbursement Insights : Understand FDA approval trends, reimbursement policies, and healthcare system adoption patterns specific to the US market, critical for commercialization planning.
    • Technology & Application Trends : Identify emerging cell therapy applications, manufacturing innovations, and clinical breakthroughs driving growth in the US market across oncology, immunotherapy, and regenerative medicine.
    • Market Entry Strategy : Develop informed go-to-market strategies with data on US healthcare provider adoption rates, patient demographics, and regional market variations for cell therapy products.

    Frequently asked questions

    What is the current size of the US cell therapy technologies market?

    The US cell therapy technologies market is estimated at $79.5 million in 2025 and is projected to grow to $134.2 million by 2030.

    What is the expected growth rate for the US cell therapy market?

    The US cell therapy technologies market is expected to grow at a compound annual growth rate (CAGR) of 11.0% from 2025 to 2030.

    What factors are driving growth in the US cell therapy market?

    Key drivers include rising chronic disease prevalence, increasing demand for personalized medicine, strong FDA regulatory pathways, and significant biotech R&D investments in the US.

    How does the US cell therapy market compare to global trends?

    The US market grows at 11.0% CAGR, slightly below the global rate of 12.4%, reflecting the US's mature market position and established competitive landscape.

    What role does FDA regulation play in the US cell therapy market?

    The FDA provides clear approval pathways and regulatory frameworks that encourage innovation and commercialization, positioning the US as a global leader in cell therapy development and adoption.

    RESEARCH METHODOLOGY

    This research study utilized extensive secondary sources, directories, and databases to identify and collect valuable information for analyzing the global cell therapy technologies market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to gather and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was primarily used to identify and collect information for the comprehensive, technical, market-oriented, and commercial study of the cell therapy technologies market. The secondary sources used for this study include FDA (US Food and Drug Administration), EMA (European Medicines Agency), NIH (National Institutes of Health), ClinicalTrials.gov, PMDA (Pharmaceuticals and Medical Devices Agency, Japan), MHRA (Medicines and Healthcare products Regulatory Agency, UK), European Society of Gene and Cell Therapy (ESGCT), California Institute for Regenerative Medicine (CIRM), World Health Organization (WHO), International Society for Cell & Gene Therapy (ISCT), CBER (Center for Biologics Evaluation and Research), NIH Regenerative Medicine Program, National Medical Products Administration (NMPA), China, Health Canada – Biologics and Genetic Therapies Directorate (BGTD), Eurostat, Factiva, and GLOBOCAN, ScienceDirect; research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations, among others. These sources were also utilized to gather key information about major players, market classification, and segmentation, as well as industry trends, regional/country-level markets, market developments, and technological perspectives.

    Primary Research

    After acquiring foundational knowledge about the global cell therapy technologies market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from biopharmaceutical & biotechnology companies, CROs and CMOs, research institutes, and cell banks. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.

    These interviews spanned six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    Cell Therapy Technologies Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell therapy technologies market. These methods were also used extensively to estimate the size of various market segments. The research methodology used to estimate the market size includes the following:

    After determining the overall market size through the estimation process, the total market was divided into several segments and subsegments.

    Cell Therapy Technologies Market

    Data Triangulation

    After determining the market size through the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, as applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Cell therapy is a transformative area that represents a groundbreaking advancement in modern medicine, leveraging living cells to repair, replace, or regenerate damaged tissues and treat a wide range of diseases. This innovative approach involves introducing functional cells into a patient’s body to restore health, offering solutions for conditions that were once considered untreatable. With applications spanning autologous therapies, which utilize a patient’s cells, and allogeneic therapies, offering scalable off-the-shelf solutions, cell therapy is transforming healthcare delivery. The report encompasses a range of media, sera, reagents, cell engineering products, cell therapy equipment, software, and other products utilized at various stages of cell therapy, including cell collection, manufacturing, expansion, and storage.

    Stakeholders

    • Cell therapy product manufacturers, suppliers, and processors
    • Distributors and suppliers of cell therapy products
    • Biotechnology and biopharmaceutical companies
    • Contract manufacturing organizations (CMOs)
    • Suppliers and distributors of pharmaceutical products
    • Research and development (R&D) companies
    • Pharmaceutical/medical associations
    • Trade associations and industry bodies
    • Regulatory bodies and government agencies
    • Research institutes and government organizations
    • Venture capitalists and investors
    • Business research and consulting service providers
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the cell therapy technologies market based on product, process, cell type, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall cell therapy technologies market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the global cell therapy technologies market and comprehensively analyze their product portfolios, market positions, and core competencies2
    • To track and analyze competitive developments such as product launches, acquisitions, partnerships, expansions, agreements, and collaborations in the cell therapy technologies market
    • To benchmark players within the cell therapy technologies market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and business strategy

     

    Get the Full Cell Therapy Technologies Market Report

    Full forecast, segment splits, and company analysis for all Cell Therapy Technologies Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status